
Aflac (AFL) Stock Forecast & Price Target
Aflac (AFL) Analyst Ratings
Bulls say
Aflac Inc. demonstrated a robust financial performance, with pretax adjusted earnings in the Japan segment soaring by 24% year-over-year to ¥159 billion, alongside a notable increase in the pretax adjusted margin to 44.7%, aided by significant remeasurement gains. Furthermore, the company achieved a 6% rise in new sales in the U.S. to $379 million, supported by strong demand for premier group life and disability products, while Japan experienced a 12% growth in new annualized premium sales to ¥17.5 billion, reflecting positive reception of its new product offerings. Lastly, Aflac reported an operating EPS of $2.16, marking a 17% year-over-year increase, indicative of the company’s strong earnings emergence amidst ongoing efforts to enhance the value proposition of its insurance products.
Bears say
Aflac Inc. has encountered significant challenges leading to a negative outlook, primarily reflected in a 27% decrease in pretax adjusted earnings to $350 million in 3Q23, driven by lower remeasurement gains and a notable reduction in its pretax margin. Additionally, the company's ongoing implementation issues in dental and vision products have hampered sales, and the anticipated introduction of a new cancer product in Japan may not alleviate near-term sales weaknesses. The potential deterioration of the yen due to Japanese monetary easing poses a further risk for earnings per share, contributing to investor concerns regarding the firm's financial stability.
This aggregate rating is based on analysts' research of Aflac and is not a guaranteed prediction by Public.com or investment advice.
Aflac (AFL) Analyst Forecast & Price Prediction
Start investing in Aflac (AFL)
Order type
Buy in
Order amount
Est. shares
0 shares